LAWRENCE, Mass., Jan. 24, 2011 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced the addition of Nancy J. Ham to the Company's Board of Directors and the resignation of Jonathan T. Silverstein.
Mr. Silverstein, General Partner of OrbiMed, joined NxStage's Board in connection with the Company's 2008 financing, in which OrbiMed was the lead investor. "Jonathan has been a tremendous asset to NxStage helping set the future strategic direction for the Company," said Jeff Burbank, Chief Executive Officer of NxStage Medical. "As we work to further strengthen our market leadership in renal care, we are excited to add someone of Nancy's caliber and industry background to our Board. Nancy is a strong executive and we look forward to benefiting from her insights and experience."
Ms. Ham is currently President, CEO and director of MedVentive, Inc., a leading provider of physician performance management solutions for healthcare delivery networks and payers. Previously, she served as President of Sentillion, Inc. Before joining Sentillion, Ms. Ham served in various executive capacities at ProxyMed, Inc., including President and COO, and Healtheon/WebMD Corporation.
"I'm very excited about contributing to the growth that I believe NxStage has ahead of them, and to improving patient access around the world to the many reported benefits of daily home therapy with the NxStage System One™," said Ms. Ham.
About NxStage Medical, Inc.NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of End Stage Renal Disease (ESRD) and acute kidney failure. For mo
|SOURCE NxStage Medical, Inc.|
Copyright©2010 PR Newswire.
All rights reserved